Market News AIOpen the app

Chardan Capital is keeping its price target at $11.00 per share for Rocket Pharmaceuticals.

OpinionRead the original at moomoo.com
Neutral

Chardan kept its $11.00-per-share target unchanged. The note reports an analyst view, not a new change in Rocket's business, so it does not shift the company's outlook.

RCKT · Rocket Pharmaceuticals, Inc.

AI read · Neutral

The AI's read

That leaves Chardan's view unchanged, rather than adding new evidence about Rocket's business. The note reports no new trial results, sales, or company forecast, so it does not change how we read the company.

Get alerts for RCKT

Follow Rocket Pharmaceuticals, Inc. (RCKT) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for RCKT
Free on the App Store and Google Play, or on the web.